Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...

Model Approaches for Pharmacokinetic Data: Compartment Models

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...

Pharmacokinetic Models: Overview

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A data analysis approach for locomotor behavioral responses in developmentally exposed zebrafish.

NAM journal·2026

Same author

Case study application of high-throughput new approach methodologies for exposure to the interpretation of matched biomarker and indoor media measurements.

Journal of exposure science & environmental epidemiology·2026

Same author

Incorporating a dermal absorption route into high throughput toxicokinetic modeling.

Journal of exposure science & environmental epidemiology·2026

Same author

Characterizing Accuracy of Model Predictions for Chemical Concentration in High Throughput Screening Assays.

Environmental science & technology·2026

Same author

Response to letter to the editor on: "the use of canonical dose-response models for benchmark dose analysis of continuous toxicological data".

Critical reviews in toxicology·2025

Same author

Applying New Approach Methods for Toxicokinetics for Chemical Risk Assessment.

Chemical research in toxicology·2025

Same journal

Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

Journal of pharmacokinetics and pharmacodynamics·2026

Same journal

Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

Journal of pharmacokinetics and pharmacodynamics·2026

Same journal

Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

Journal of pharmacokinetics and pharmacodynamics·2026

Same journal

Personalized prophylactic therapy optimization in hemophilia A using a hybrid PK-PD-TTE model and deep RL.

Journal of pharmacokinetics and pharmacodynamics·2026

Same journal

Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea.

Journal of pharmacokinetics and pharmacodynamics·2026

Same journal

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis.

John F Wambaugh¹, Hugh A Barton, R Woodrow Setzer

¹National Center for Computational Toxicology, US EPA, Research Triangle Park, NC 27711, USA. wambaugh.john@epa.gov

Journal of Pharmacokinetics and Pharmacodynamics

|January 9, 2009

Summary

This summary is machine-generated.

This study reveals that a two-compartment pharmacokinetic (PK) model better describes perfluorooctanoic acid (PFOA) elimination in rats than a one-compartment model. PFOA excretion shows significant sex-based differences, with males eliminating the substance much slower than females.

More Related Videos

An All-Human Hepatic Culture System for Drug Development Applications

An All-Human Hepatic Culture System for Drug Development Applications

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Jun 26, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

An All-Human Hepatic Culture System for Drug Development Applications

An All-Human Hepatic Culture System for Drug Development Applications

Published on: October 20, 2023

Area of Science:

Environmental Chemistry
Toxicology
Pharmacokinetics

Background:

Perfluorooctanoic acid (PFOA) is widely studied, often using a simplified one-compartment pharmacokinetic (PK) model.
Understanding PFOA's complex elimination pathways is crucial for accurate risk assessment.

Purpose of the Study:

To investigate and select the most appropriate PK model for PFOA using experimental data.
To analyze PFOA plasma and excretion data in rats, accounting for biological variability and measurement error.

Main Methods:

Utilized Bayesian analysis with Markov Chain Monte Carlo (MCMC) for joint analysis of plasma and excretion data.
Incrementally expanded a one-compartment PK model, evaluating improvements using Bayesian diagnostics.
Separated male and female rat data due to observed sex-dimorphic excretion patterns.

Main Results:

A two-compartment PK model demonstrated a superior fit to PFOA data compared to a one-compartment model.
Significant sex differences in PFOA elimination were confirmed; male rats exhibit slower, bi-phasic elimination.
Estimated clearances indicated substantial PFOA excretion via urine in both sexes, with minor fecal elimination.

Conclusions:

A two-compartment model is more appropriate for describing PFOA PK in rats than previously assumed.
The employed Bayesian hierarchical framework is valuable for evaluating complex PK models, including PBPK models.
Further investigation may support PK models with more than two compartments for PFOA.